-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。ウィリアムズ社は第1四半期に堅調な業績を上げ、調整後EPSは0.73ドルとなり、アナリスト予想の0.62ドルを上回り、前年同期比22%増となりました。調整後EBITDAは、トランスコ社の拡張プロジェクト、新規開発によるメキシコ湾岸地域での取扱量増加、冬の嵐による貯蔵収入増などにより、13%増の22億5000万ドルとなりました。天然ガスを中流事業の中心とする同社は、LNGインフラとデータセンター需要における戦略的なポジショニングから恩恵を受け、23億ドル規模のネオ発電プロジェクトやアトラス社のデータセンターインフラなど、主要顧客との契約を獲得しました。経営陣は、2026年の成長投資額のガイダンスを従来の61億ドル~67億ドルから70億ドル~76億ドルに引き上げ、2026年の調整後EBITDAガイダンスは80億5000万ドル~83億5000万ドルで据え置き、上半分の水準になるとの見通しを示しました。当社は、積極的な成長戦略によりWMBが長期的な需要動向にうまく対応できると考えていますが、第1四半期の設備投資額が前年同期の6億7000万ドルに対し16億4000万ドルに増加したことは、Transco全体およびデータセンタープロジェクトにおける拡張計画に必要な多額の投資を反映しています。
Related Articles
Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.
ALS Flags Unauthorized Access to Its IT Systems
ALS (ASX:ALQ) reported a cyber incident involving unauthorized third-party access to some of its information technology (IT) systems, temporarily disrupting parts of its operations, according to a Tuesday Australian bourse filing.The company, with support from external cybersecurity specialists, has implemented containment measures in line with incident response procedures, restoring most operations while continuing targeted remediation in affected areas, per the filing.The company has informed the Australian Cyber Security Center and is investigating the full extent of the breach and its potential data impact, the filing added.
Dexus Secures JV With Boral for Major Ravenhall Logistics Precinct in Melbourne
Dexus (ASX:DXS) has entered a joint venture (JV) with Boral (ASX:BLD) to develop a large-scale logistics precinct in Ravenhall, Melbourne's western corridor, spanning 630 hectares and targeting up to 2.5 million square meters of lettable space, subject to rezoning and regulatory approvals, according to a Tuesday Australian bourse filing.The JV structure gives the company and other capital partners a combined 50% stake, while Boral retains the remaining 50%, with the project developed in staged superlots and supported by substantial third-party capital to enhance capital efficiency, per the filing.The company will oversee rezoning, development, and management, with limited short-term financial impact, while management fees will begin as each stage of investment is completed, the filing added.